Natural history of α-1-atd in children

Similar documents
Dhanpat Jain Yale University School of Medicine, New Haven, CT

Alpha-1 Liver Disease

Liver Disease in Cystic Fibrosis

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Hepatic sinusoidal obstruction syndrome due to herbal ingestion in South African children - An 8 year review

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Interpreting Liver Function Tests

EVALUATION OF ABNORMAL LIVER TESTS

Liver failure &portal hypertension

CHAPTER 1. Alcoholic Liver Disease

Module 1 Introduction of hepatitis

Non-Alcoholic Fatty Liver Disease

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

Pediatric PSC A children s tale

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

Hepatitis and pregnancy

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Alpha-1 Antitrypsin Deficiency: Liver Disease

Jaundice. Agnieszka Dobrowolska- Zachwieja, MD, PhD

Neonatal Cholestasis. What is Cholestasis? Congenital and Pediatric liver diseases 4/26/18

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

Healthy Liver Cirrhosis

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

Drug-induced liver injury

Follow-up of pediatric chronic liver disease

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

Case n 1 ( B 92 / 4208 ) Case n 2 ( B 00 / 8249 ) Case n 3 ( B 98 / 8352 )

Patterns of abnormal LFTs and their differential diagnosis

Hepatology For The Nonhepatologist

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths

Metabolic Liver Disease

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Liver disease in adults with severe alpha-1-antitrypsin deficiency

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

Liver Failure. The most severe clinical consequence of liver disease is liver failure:

AATD is systemic disorder which involve GI tract: Liver Pancreas Intestine

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Special stains in liver pathology

Case report Idiopathic neonatal hepatitis or extrahepatic biliary atresia? The role of liver biopsy

Hangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam

PREVALENCE OF NAFLD & NASH

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

HIV. KEY WORDS: HIV, esophageal varices, endoscopic injection sclerotherapy (EIS), endoscopic variceal ligation (EVL)

Current Management of Biliary Atresia. Janeen Jordan, MD PGY5 Surgery Grand Rounds November 19, 2007

Liver disease in cystic fibrosis

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

Liver Pathology in the 0bese

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

The most common form of 1 -antitrypsin (A1AT) deficiency REVIEWS. Diagnosis and Management of Patients With 1 -Antitrypsin (A1AT) Deficiency

Hepatology for the Nonhepatologist

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

Hepatitis Panel/Acute Hepatitis Panel

DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL

Diagnosis and Management of PBC

World Health Organization. Western Pacific Region

Liver Diseases. Yasmine Lashine MD, PhD

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology

Western Health Specialist Clinics Access & Referral Guidelines

Research Article Mortality of Biliary Atresia in Children Not Undergoing Liver Transplantation in Egypt (Single Institutional Study)

A lpha 1-antitrypsin (AAT) deficiency is an autosomal. Factors Associated With Advanced Liver Disease in Adults With Alpha 1 -Antitrypsin Deficiency

Primary Biliary Cholangitis

Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1

2. Description of the activity

Adults with Inherited Liver Diseases

Entrustable Professional Activity

Patterns of abnormal LFTs and their differential diagnosis

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Pediatric Primary Sclerosing Cholangitis and Potential Therapies

Overview of PSC Making the Diagnosis

Hepatitis Panel/Acute Hepatitis Panel

HOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO

AMR in Liver Transplantation: Incidence

Liver Pathology Symposium - medical livers

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.

Learning Objectives. After attending this presentation, participants will be able to:

Clinical Trials & Endpoints in NASH Cirrhosis

Screening for Portal Hypertension in Cirrhosis

Hepatitis C Update on New Treatments

Primary Sclerosing Cholangitis Medical Management

Current Concepts in the Management and Treatment of PBC & PSC

Transcription:

Natural history of α-1-atd in children Agnieszka Bakuła Dpt of Gastroenterology, Hepatology, Nutrition Disorders and Paediatrics The Children s Memorial Health Institute Warsaw, Poland Topics to be discussed ATD- liver symptoms natural history risk factors of bad prognosis patomechanisms of liver injury liver transplantation in ATD What s new in ATD in Poland? 2

Liver manifestations- infancy neonatal hepatitis: prolonged obstructive jaundice (pale stools) bleeding symptomes: bleeding from umbilical stump hematemesis melena intraventicular hemorrhage 3 Liver manifestations- early childhood elevated transaminases (incidentally) asymptomatic hepatomegaly jaundice during an intercurrent illness severe liver dysfunction 4

Liver manifestationslate childhood/ adolescence chronic active hepatitis portal hypertension: ascites, coagulopathy esophageal varices, gastrointestinal bleeding cryptogenic cirrhosis hepatocellular carcinoma 5 The course of liver disease 10-20% children with neonatal hepatitis are reported to develop advanced liver disease on histological criteria DIFFICULTY IN SELECTING WHICH CHILDREN AND WHEN NEED LTx 6

Natural history- Sveger study 1972-1974: Swedish nationwide screening study: 200.000 infants 127 PiZZ, followed to now 14: prolonged obstructive jaundice, 9/14- clinically significant liver disease 8: hepatomegaly Sveger T. N Engl J Med 1976;294:1316 1321 7 During 12 years observation None clinical symptoms of liver disease 5 pts died: 3 of liver cirrhosis, Bil levels: 11% of infants, normalization till 6/12 ALT: from 73% in infants to 15% at 12y GGTP: from 50% of infants to 3% Sveger T. 1998 Acta Paediatr Scand 77:847 8518

6%- marginal increase of ALT 7%- elevated GGT liver biopses have not been conducted 9 Center experience - patients and methods screening from 1978 to 2008 76 children (20, 56 ) age at diagnosis: 0.1-9 y PiZZ phenotype follow up: - at least 10 years (good prognosis group) - or to Ltx or death (bad prognosis group) 10

Dead 4(5%) The results Ltx-14 (18%) Good prognosis 58 (77%) 11 The outcome of the 76 children with alpha-1-atd The results 7 2 Hepatitis+cholest asis: 44 (58%) 10 13 44 Cholestasis 13 (17%) with no symptoms 10 (13%) hepatitis 7 (9%) The first symptoms of the 76 children with alpha-1-atd 12

The results 100% 80% ns p<0,01 p<0,01 60% 40% good prognosis bad prognosis 20% 0% 1 year 4-7 y 9-14 y The frequency of hepatitis in the group with good and bad prognosis depending on age 13 The results 100% 80% p<0,05 p<0,001 p<0,001 60% 40% Good prognosis Bad prognosis 20% 0% 1 year 4-7 y 9-14 y The frequency of cholestasis in the group with good and bad prognosis depending on age 14

Conclusions the prognosis in most of the patients with α-1 ATD was good hepatitis and cholestasis were the most frequent presenting symptoms of ATD in children cholestasis in 1y and at later ages and hepatitis at later ages were risk factors of bad prognosis 15 Risk factors (Ltx)- 97 patients: jaundice for over than 6 weeks higher AST at presentation higher AST and GGTP during follow up initial liver biopsy: severe bile duct proliferation, bridging septa and/or severe fibrosis 16

The role of: male sex low birth weight were not confirmed 17 The prognosis in childhood of liver disease associated with alpha 1-ATD (PiZZ). Parameters associated with poor prognosis and death from within 2 weeks to 4 years: persistent hypoalbuminaemia the presence of ascites persistent or recurrent jaundice coagulopathy not responded to vitamin K variceal bleeding Psacharopoulos HT, et al. 18 Japan Medical Research Foundation (eds) Cholestasis in Infancy.1990; 133-140

The patomechanism of liver injury - gain-of-toxic function mechanism of liver damage - defective mechanisms of mutated protein disposal: autophagy and proteosome - genetic/environmental modifiers predispose/protect? accumulation of mutant ATZ in ER 19 Liver biopsy in ATD periodic acid Shiff positive, diastase resistant globules in the ER: With permission of M. Pronicki

Liver biopsy in ATD inflammatory cell infiltration With permission of M. Pronicki 21 Liver biopsy in ATD periportal fibrosis With permission of M. Pronicki 22

Liver biopsy in ATD steatosis: macrovacuolar or mixed With permission of M. Pronicki 23 Liver biopsy in ATD bile duct proliferation With permission of M. Pronicki 24

Liver biopsy in ATD EM: progressive mitochondrial autophagy Grant no 2011/01/D/NZ5/01392 25 Treatment in children no specific therapy for liver disease supportive management of liver dysfunction symptomes: vit. A, D, E, K, ursodeoxycholic acid (UDCA) portal hypertension management 26

Treatment in children prevention of complications: propranolol sclerotherapy, variceal endoscopic binding 27 Treatment in children autophagy enhancing drug??? karbamazepine, rapamycin 28

An autophagy-enhancing drug promotes degradation of mutant ɑ-1 antitrypsin Z and reduces hepatic fibrosis Carbamazepine: used safely for many years for seizures and depression the autophagy-enhancing drug decreases the hepatic load of ɑ-1atz reverses hepatic fibrosis (mice models) This idea has profound implications for therapy in children Hidvegi T, et al. Science 2010;329(5988):229-32 29 Treatment in children liver transplantation(ltx)- the causative treatment! 30

Liver transplantation/2013 17 pts: 5, 12 age at LTx: 14.3 (0.7-17.1)years (two infants - 8 and 9 months of age) >10 r.ż.- 14/17 pts oesophageal varices- 14/17 variceal bleeding- 6/17 ascites: 4/17 1-year patient survival after Ltx: 100% 5-year patient survival: 87.5% 31 5-year patient survival after Ltx Author-No pts Age at Ltx (years) 5-year patient survival Follow up (years) Hughes et al.- 35 6 76,5% >10 y (1-9) 50% patients Esquivel et al.- 29 5 (8 mo-13 years) Francavilla et al.- 24 3,8 (6 mo-15 years) IP CZD- 17 14,3 (8 mo-17,1 years) 83% 2,3 years 92% 3,9 y 87,5% 10,3 y

Does the heterozygous state of ɑ-1-atd have a role in chronic liver diseases? no association: the heterozygous PiZ state and the chronic LD/ cryptogenic cirrhosis a significantly higher prevalence of PiMZ in pts with decompensated LD of any etiology compared with patients with compensated LD a significant association between the PiMZ state and the need for liver transplantation in pts with HCV or NAFLD Rogev A, Guaqueta C, Molina EG et al. JPGN, 2006, 43: S30-S35 33 The project supported by National Science Centre, 2011-2015 the aim: to determine distinctive features of hepatocytes ultrastructure (mitochondria abnormalities and autophagy in particular) in children with variable course of α-1-atd Grant no 2011/01/D/NZ5/01392 34

The project supported by National Science Centre, 2011-2015 a specific pattern of proteins expression in EM associated with the disposal of the mutated Z protein in patients with good and poor prognosis a marked increase of mitophagy and autophagy in hepatocytes in the group with good prognosis - role in more efficient degradation α-1-at protein? - significant feature of favourable prognosis in children with α-1-atd? 35 Retrospective study of the natural history of childhood alpha-1 antitrypsin deficiency associated liver disease 2015/2016 approximately 600 patients in 4 European centers 150 Polish patients (50 patients currently controlled in outpatient clinic) to identify indicators of a poor prognosis (progression to portal hypertension) to characterize the natural history of disease progression in some children with ATD 36